Sigma-Aldrich Corp

Sigma-Aldrich — Shareholder Meeting (May 2010)

26 slides from Sigma-Aldrich's shareholder meeting presentation, May 4, 2010

  1. Slide 1: Sigma-Aldrich Corporation 2010 Shareholders Meeting

    Sigma-Aldrich Corporation 2010 Shareholders Meeting Enabling Science to Improve Quality of Life May 4, 2010 Exhibit 99.1

  2. Slide 2: Cautionary Statement

    Cautionary Statement Our presentation today will include forward-looking statements relating to the Company’s future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including expectations, goals, beliefs, intentions and the like regarding future sales, earni

  3. Slide 3: Agenda

    Agenda 2009 Business and Financial Highlights Our Company Plans for Growth First Quarter Results and Full Year 2010 Outlook

  4. Slide 4: Our Objectives

    Mission – Enabling science to improve the quality of life Vision – To be the trusted global partner of choice for our customers Objective – To deliver sustainable above-market growth and create value for our Employees, Customers and Shareholders by building on our core capabilities and leveraging ou

  5. Slide 5: Diversified approach to yield consistent returns

    Diversified approach to yield consistent returns Who is Sigma-Aldrich? Delivering Value Through a Balanced Portfolio

  6. Slide 6: Who is Sigma-Aldrich?

    70% Research Consumables 30% Fine Chemicals & Services • Research Business • Manufacturing (SAFC) A leading Life Science company enabling researchers and manufacturers to improve the quality of life Who is Sigma-Aldrich? • Customers – Academia – Pharma & Biotech – Industrial – Hospitals – Testing La

  7. Slide 7: 2009 Financial Highlights

    Strong performance in a challenging economy 2009 Financial Highlights Record Year for Earnings and Free Cash Flow

  8. Slide 8: Historical Performance – Profitable Sales Growth

    35 years of continuous EPS growth Historical Performance – Profitable Sales Growth • Demonstrated historic performance • Robust business model

  9. Slide 9: Historical Performance – Shareholder Returns

    • Returns Consistently deliver superior returns Historical Performance – Shareholder Returns • Sustained high returns • Shareholder returns outperformed peers and broad market indices Peers: Affymetrix, Cambrex, Dionex, Illumina, Life Technologies, Millipore, Qiagen, Techne, Thermo-Fisher, Waters $1

  10. Slide 10: Key Business Highlights

    Supporting the advancement of science, education, innovation, thought leadership and environmental sustainability 2009 Highlights Key Business Highlights • Research Biotech growth drivers – Innovative new antibody products – Regenerative medicine • Fine Chemicals (SAFC) benefits from sale of H1N1 va

  11. Slide 11: Awards and Recognitions

    • Research Biotech • SAFC • Sigma - Aldrich 2009 Highlights Awards and Recognitions • Top 5 Innovations of 2009 for knockout rat – The Scientist magazine • 2009 North America Healthcare Innovation Award – Frost & Sullivan • 2009 CIO 100 award for innovative web research tool, Your Favorite Gene powe

  12. Slide 12: Commitment to Corporate Citizenship

    • Team 2009 Highlights Commitment to Corporate Citizenship Sigma-Aldrich Celebrates 5th Anniversary • 1,300 employees participated in 23 events • Introduced two new sites to the program – Castle Hill, Australia – Oakville, Canada • Employees gave back over 4,200 hours of service • Events: – Habitat

  13. Slide 13: First Quarter 2010 Financial Results vs. Prior Year

    YEAR-OVER-YEAR Diluted EPS, excluding restructuring costs were $0.84, 24% higher than the same period last year First Quarter 2010 Financial Results vs. Prior Year Diluted EPS Net Income Sales $572 $100 $0.81 Q1 2010 (in millions, except EPS) 10 % 19 % 19 % As Reported Free Cash Flow $133 55 % 4 % 1

  14. Slide 14: 2010 Outlook

    2010 Outlook Free Cash Flow Reported EPS Organic Revenue Growth $3.05 to $3.20 > $350 million Mid single digits

  15. Slide 15: Objectives: 2010-2014

    Strategic actions build sustainable value Five-Year Financial Targets Incremental Impact Objectives: 2010-2014 Top line organic growth (normal economic conditions) 7-8% Expand cumulative operating margins by 2014 200-300 bpts Cumulative free cash flow (five years) > $2 Billion • Deliver above-market

  16. Slide 16: Plan to Achieve Objective: Top Line Growth Initiatives

    Initiatives 4% incremental contribution to top line growth Plan to Achieve Objective Top Line Growth Initiatives Innovation ABC M Focus Analytical Expand into attractive areas of detection and analysis Biology Increase focus on biology Expand traditional product portfolio and build new targeted plat

  17. Slide 17: Impact of Top-Line Growth

    Impact of Top-Line Growth Initiatives to achieve above market growth rates

  18. Slide 18: Plan to Achieve Objective: Expand Operating Margins

    Leverage core competencies through targeted initiatives to create value Plan to Achieve Objective Expand Operating Margins Portfolio optimization Capacity utilization Focus on differentiation Sourcing knowledge Competitive pricing strategies Operational excellence Optimize supply chain Leverage proc

  19. Slide 19: Profitability Drivers

    Net 200-300 basis point improvement in operating margin over five years Profitability Drivers Impact of Initiatives

  20. Slide 20: Future Uses of Cash

    Expect free cash flow to be in excess of $2 billion over next five years Future Uses of Cash 2010 and Beyond • Fund organic growth through technology, partnerships, licensing and go-to-market investments • Fund inorganic growth • Cash dividends • Share repurchases • Debt reduction

  21. Slide 21: Investments for Growth

    Infrastructure remains a key differentiator as we drive demand • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center

  22. Slide 22: Investments for Growth

    Infrastructure remains a key differentiator as we drive demand • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics

  23. Slide 23: Investments for Growth

    Infrastructure remains a key differentiator as we drive demand • • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics Carlsbad, California • Capacity expansion to produce viral vacc

  24. Slide 24: Investments for Growth

    Infrastructure remains a key differentiator as we drive demand • • • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics Carlsbad, California • Capacity expansion to produce viral va

  25. Slide 25: Compelling investment opportunity

    Compelling investment opportunity Sigma-Aldrich Uniquely Positioned for Value Creation Unrivaled scientific knowledge and unsurpassed service Diversified portfolio: products, customers Expanding global footprint History of profitable growth Strong financial position and cash flow Plans to enhance gr

  26. Slide 26: Sigma-Aldrich Corporation – Questions?

    Sigma-Aldrich Corporation 2010 Shareholders Meeting Enabling Science to Improve the Quality of Life Questions ?

Sigma-Aldrich — Shareholder Meeting (May 2010) on 6ix